2. NCCN Guidelines Version 2. 2023 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 3. Sharman, Jeff P., et al. "Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive ...
7. NCCN Guidelines CLL/SLL Version 1.2024 8. Miao Y, Sha Y, Xia Y, et al. Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 ab...
[5]Hallek M, Cheson BD, Catovsky D,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. PMID: 29540348. [6]Wierda WG, Raws...
A.2; Paik, J.2; Shadman, M.11,12. P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL. HemaSphere
2023年5月8日,根据国家药品监督管理局(NMPA)网站最新信息[1],新一代BTK抑制剂百悦泽®(泽布替尼)在中国迎来新获批,用于一线治疗成人慢性淋巴细胞白血病(CLL)或小淋巴细胞淋巴瘤(SLL)患者和成人华氏巨球蛋白血症(WM)患者。 中国临床肿瘤学会(CSCO)监事会监事长、哈尔滨血液病肿瘤研究所所长马军教授表示:“泽布替...
[9] Annals of Oncology, Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, January 6, 2020.[10] Cerhan, J.R. and T.M. Habermann, Epidemiology of Marginal Zone Lymphoma. Ann Lymphoma, 2021.[11] Smith, A., et al., Lymphoma incidence, ...
Treatment recommendations for patients with del (17p) Although these patients have a poor prognosis and there is no clear standard of care, the National Comprehensive Cancer Network (NCCN) guidelines list the following as preferred regimens for first-line treatment[12]: ...
Exploring Fixed-Duration Ibrutinib and Venetoclax in CLL Treatment Guidelines for Mesothelioma Now Offer More Treatment Options Immunotherapy Advances in Small Cell Lung Cancer Treatment Ide-cel in Multiple Myeloma Post-Transplant: Insights From Garfall ...
CALQUENCE® (acalabrutinib) is a BTK inhibitor indicated for the treatment of adult patients with R/R Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
[9] Annals of Oncology, Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, January 6, 2020. [10] Cerhan, J.R. and T.M. Habermann, Epidemiology of Marginal Zone Lymphoma. Ann Lymphoma, 2021. ...